YZi Labs has appointed Jane He as General Partner to spearhead its investments in biotechnology, representing a strategic move beyond its established focus on Web3.
This development follows the organization’s recent rebranding from its previous identity and underscores a heightened focus on artificial intelligence and biotech.
Jane He comes into this role as a seasoned investor with substantial experience in biotech and medtech. She will be instrumental in discovering and nurturing groundbreaking innovations in these fields. Her background includes work in cancer therapies, gene editing, metabolic treatments, and AI-driven solutions in biotechnology.
Prior to her position at YZi Labs, He functioned as an investor and Chief Operating Officer at a hedge fund based in Hong Kong, where her responsibilities centered around growth-stage biotech ventures.
Her prior leadership experience at PAAMCO Prisma also provided her with a comprehensive understanding of investment management across the Asian market.
Ella Zhang, the head of YZi Labs, emphasized that He’s appointment is a significant advancement in the firm’s evolving investment philosophy.
“We are thrilled to welcome Jane to our team at YZi Labs. She is not only an exceptional investor but also has an entrepreneurial spirit committed to enacting meaningful change. As we broaden our investment areas to include AI and biotech alongside Web3, we are cultivating a team rich in specialized knowledge and passionate about exploring interdisciplinary innovations to propel our vision,” Zhang remarked.
AI, Biotech, and Web3
Jane He’s appointment is indicative of YZi Labs’ comprehensive approach to fostering transformative innovations at the convergence of AI, biotech, and Web3.
Biotechnology is currently witnessing rapid progress, with artificial intelligence increasingly facilitating drug discovery, enhancing diagnostics, and enabling personalized medicine. The intersection of these domains unveils new opportunities for investors and entrepreneurs, a pathway that YZi Labs is eager to explore.
The firm is proactively searching for visionary founders who are pushing the boundaries of technology in Web3, AI, and biotech.